类他类药物通过降低胆固醇,抑制α-synuclein的细胞间传播
Joo-Ok Min1, Hoang-Anh Ho2, Wonjae Lee1,3
1Department of Biomedical Sciences, Neuroscience Research Institute, Convergence Research Center for Dementia, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
像simvastatin一样,他类药物可以通过降低大脑胆固醇水平来减少涉及神经退行性疾病的有毒蛋白质聚合物的传播. 这一发现为帕金森病等疾病提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白质聚合物的细胞间传播,包括α-synuclein和突变的huntingtin (mHtt),是神经退行性疾病进展的关键因素.
- 控制这种传播的精确机制和调节器仍然不完全理解,需要进一步研究潜在的治疗点.
研究的目的:
- 识别能够抑制α-synuclein和突变huntingtin (mHtt) 细胞间传播的小分子.
- 研究大脑胆固醇合成在已识别的治疗药物的疗效中的作用.
主要方法:
- 一个小分子库的选,以识别α-synuclein和mHtt传播的抑制剂.
- 在转基因同核蛋白病变模型中使用simvastatin和pravastatin.
- 使用培养细胞对细胞内胆固醇水平进行基因或药理学操纵.
- 使用预制纤维素注射的小鼠模型与高脂肪饮食干预.
主要成果:
- 在转基因小鼠模型中,simvastatin,但不是pravastatin,改善了行为缺陷和减少了α-synuclein积累,这表明大脑透和胆固醇合成抑制是关键.
- 在培养细胞中细胞内胆固醇水平升高会增加α-synuclein的聚合和分泌.
- 通过甲基β-环氧或他类药物降低胆固醇,可以逆转胆固醇载荷细胞中的α-synuclein聚合和分泌.
- 高脂肪饮食加剧了α-synuclein病理,simvastatin可以逆转这种影响.
结论:
- 类他类药物,特别是simvastatin,通过减少大脑胆固醇合成来抑制像α-synuclein这样的蛋白质聚合物的传播.
- 胆固醇的积累似乎促进了α-synuclein的聚合和传播,突出了胆固醇代谢作为神经退行性疾病的治疗点.
更多相关视频
09:16Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
08:24A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Regulation of Nuclear Protein Sorting
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
